BDRX
Income statement / Annual
Last year (2024), Biodexa Pharmaceuticals Plc's total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Biodexa Pharmaceuticals Plc's net income was -$5.73 M.
See Biodexa Pharmaceuticals Plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$381.00 K |
$699.00 K |
$578.00 K |
$343.00 K |
$674.00 K |
$1.94 M |
$989.00 K |
$1.32 M |
$1.38 M |
| Cost of Revenue |
$5.44 M
|
$4.07 M
|
$5.11 M
|
$4.65 M
|
$6.07 M
|
$7.84 M
|
$9.36 M
|
$8.33 M
|
$7.73 M
|
$70.00 K
|
| Gross Profit |
-$5.44 M
|
-$3.69 M
|
-$4.41 M
|
-$4.08 M
|
-$5.73 M
|
-$7.17 M
|
-$7.42 M
|
-$7.34 M
|
-$6.41 M
|
$1.31 M
|
| Gross Profit Ratio |
0
|
-9.67
|
-6.31
|
-7.05
|
-16.69
|
-10.64
|
-3.83
|
-7.42
|
-4.84
|
0.95
|
| Research and Development Expenses |
$5.44 M
|
$4.07 M
|
$5.11 M
|
$4.65 M
|
$16.15 M
|
$7.84 M
|
$9.36 M
|
$9.83 M
|
$7.73 M
|
$8.71 M
|
| General & Administrative Expenses |
$3.79 M
|
$4.34 M
|
$4.54 M
|
$2.95 M
|
$4.96 M
|
$3.84 M
|
$4.39 M
|
$4.27 M
|
$3.25 M
|
$2.08 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$323.00 K
|
$0.00
|
$170.00 K
|
$0.00
|
$605.00 K
|
| Selling, General & Administrative Expenses |
$3.79 M
|
$4.34 M
|
$4.54 M
|
$2.95 M
|
$4.96 M
|
$4.16 M
|
$4.39 M
|
$4.44 M
|
$3.25 M
|
$2.69 M
|
| Other Expenses |
-$5.47 M
|
-$4.08 M
|
-$5.13 M
|
-$4.68 M
|
-$3.79 M
|
-$8.34 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$3.76 M
|
$4.33 M
|
$4.52 M
|
$2.92 M
|
$17.32 M
|
$3.67 M
|
$4.39 M
|
$5.54 M
|
$2.07 M
|
$12.59 M
|
| Cost And Expenses |
$9.20 M
|
$8.40 M
|
$9.63 M
|
$7.58 M
|
$23.38 M
|
$11.51 M
|
$13.75 M
|
$13.87 M
|
$9.80 M
|
$12.66 M
|
| Interest Income |
$2.00 K
|
$83.00 K
|
$29.00 K
|
$0.00
|
$1.00 K
|
$8.00 K
|
$2.00 K
|
$15.00 K
|
$91.00 K
|
$48.00 K
|
| Interest Expense |
$0.00
|
$41.00 K
|
$53.00 K
|
$44.00 K
|
$34.00 K
|
$97.00 K
|
$587.00 K
|
$109.00 K
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$117.00 K
|
$283.00 K
|
$174.00 K
|
$403.00 K
|
$1.22 M
|
$1.29 M
|
$1.11 M
|
$1.17 M
|
$4.35 M
|
$736.00 K
|
| EBITDA |
-$9.08 M |
-$7.16 M |
-$8.26 M |
-$5.66 M |
-$22.22 M |
-$9.54 M |
-$10.70 M |
-$10.61 M |
-$5.30 M |
-$10.49 M |
| EBITDA Ratio |
0
|
-18.8
|
-11.82
|
-9.79
|
-64.78
|
-14.16
|
-5.52
|
-10.73
|
-4.01
|
-7.63
|
| Operating Income Ratio |
0
|
-21.03
|
-12.78
|
-12.11
|
-67.17
|
-16.79
|
-6.1
|
-11.91
|
-7.3
|
-7.34
|
| Total Other Income/Expenses Net |
$3.22 M
|
$529.00 K
|
$444.00 K
|
$892.00 K
|
-$430.00 K
|
$395.00 K
|
-$585.00 K
|
-$1.19 M
|
$1.26 M
|
$1.69 M
|
| Income Before Tax |
-$5.98 M
|
-$7.49 M
|
-$8.49 M
|
-$6.11 M
|
-$23.47 M
|
-$10.92 M
|
-$12.40 M
|
-$12.97 M
|
-$8.39 M
|
-$11.23 M
|
| Income Before Tax Ratio |
0
|
-19.65
|
-12.14
|
-10.56
|
-68.43
|
-16.21
|
-6.4
|
-13.11
|
-6.34
|
-8.17
|
| Income Tax Expense |
-$250.00 K
|
-$406.00 K
|
-$832.00 K
|
-$646.00 K
|
-$1.28 M
|
-$1.79 M
|
-$2.03 M
|
-$1.27 M
|
-$2.23 M
|
-$1.13 M
|
| Net Income |
-$5.73 M
|
-$7.08 M
|
-$7.66 M
|
-$5.46 M
|
-$22.19 M
|
-$10.09 M
|
-$10.37 M
|
-$11.71 M
|
-$6.16 M
|
-$10.10 M
|
| Net Income Ratio |
0
|
-18.58
|
-10.95
|
-9.45
|
-64.69
|
-14.96
|
-5.35
|
-11.84
|
-4.66
|
-7.34
|
| EPS |
-115700 |
-22900 |
-494300 |
-352500 |
-1432700 |
-3255700 |
-48530800 |
-51869600 |
-65101700 |
-32609000 |
| EPS Diluted |
-115700 |
-22900 |
-494300 |
-352500 |
-1432700 |
-3255700 |
-48530800 |
-51869600 |
-65101700 |
-32609000 |
| Weighted Average Shares Out |
$619.52 K
|
$309.00
|
$15.00
|
$15.00
|
$15.00
|
$3.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Weighted Average Shares Out Diluted |
$619.52 K
|
$309.00
|
$15.00
|
$15.00
|
$15.00
|
$3.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
